{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:41:23Z","timestamp":1790192483328,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004769","name":"Universit\u00e0 degli Studi di Pavia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Thyroid cancer is the most common endocrine malignancy. Current therapies are successful, however some patients progress to therapeutically refractive disease. The immunotherapeutic potential of the CXCL8-chemokine\/CXCR2-chemokine-receptor system is currently being explored in numerous human cancers. This study aimed to evaluate if the targeting of CXCR2 by its selective antagonist, AZD5069, could modulate CXCL8-mediated pro-tumorigenic effects in thyroid-cancer (TC) cells in vitro.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Normal human primary thyroid cells (NHT) and TC cell lines TPC-1 (RET\/PTC), BCPAP, 8505C and 8305C (BRAFV600e) were treated with AZD5069 (100\u00a0pM-10\u00a0\u00b5M) over a time-course. Viability and proliferation were assessed by WST-1 and crystal violet assays. CXCL8 and CXCR2 mRNA were evaluated by RT-PCR. CXCL8-protein concentrations were measured in cell culture supernatants by ELISA. CXCR2 on cell surface was evaluated by flow-cytometry. Cell-migration was assessed by trans-well-migration chamber-system.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>AZD5069 exerted negligible effects on cell proliferation or viability. AZD5069 significantly reduced CXCR2, (but not CXCL8) mRNAs in all cell types. CXCR2 was reduced on the membrane of some TC cell lines. A significant reduction of the CXCL8 secretion was found in TPC-1 cells (basal-secretion) and NHT (TNF\u03b1-induced secretion). AZD5069 significantly reduced basal and CXCL8-induced migration in NHT and different TC cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our findings confirm the involvement of the CXCL8\/CXCR2-axis in promoting pro-tumorigenic effects in TC cells, further demonstrating its immunotherapeutic significance in human cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40618-024-02410-6","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T15:02:01Z","timestamp":1718895721000},"page":"53-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro"],"prefix":"10.1007","volume":"48","author":[{"given":"F.","family":"Coperchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Petrosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Teliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cal\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pignatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-2334","authenticated-orcid":false,"given":"M.","family":"Rotondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"issue":"18","key":"2410_CR1","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","volume":"295","author":"L Davies","year":"2006","unstructured":"Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973\u20132002. JAMA 295(18):2164\u20132167","journal-title":"JAMA"},{"issue":"6","key":"2410_CR2","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1210\/er.2019-00085","volume":"40","author":"DSA McLeod","year":"2019","unstructured":"McLeod DSA, Zhang L, Durante C, Cooper DS (2019) Contemporary debates in adult papillary thyroid cancer management. Endocr Rev 40(6):1481\u20131499","journal-title":"Endocr Rev"},{"issue":"3","key":"2410_CR3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"CGAR Network","year":"2014","unstructured":"Network CGAR (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676\u2013690","journal-title":"Cell"},{"issue":"17","key":"2410_CR4","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers14174287","volume":"14","author":"F Pani","year":"2022","unstructured":"Pani F, Caria P, Yasuda Y, Makoto M, Mariotti S, Leenhardt L et al (2022) The immune landscape of papillary thyroid cancer in the context of autoimmune thyroiditis. Cancers 14(17):4287","journal-title":"Cancers"},{"issue":"4","key":"2410_CR5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","volume":"10","author":"M Pizzato","year":"2022","unstructured":"Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C et al (2022) The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol 10(4):264\u2013272","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2410_CR6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1089\/thy.2016.0628","volume":"27","author":"BR Haugen","year":"2017","unstructured":"Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM et al (2017) American thyroid association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid 27(4):481\u2013483","journal-title":"Thyroid"},{"issue":"11","key":"2410_CR7","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913\u20132921","journal-title":"Cancer Res"},{"issue":"6","key":"2410_CR8","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/ERC-21-0414","volume":"29","author":"LL Cunha","year":"2022","unstructured":"Cunha LL, Ward LS (2022) Translating the immune microenvironment of thyroid cancer into clinical practice. Endocr Relat Cancer 29(6):R67\u2013R83","journal-title":"Endocr Relat Cancer"},{"key":"2410_CR9","volume":"11","author":"E Menicali","year":"2020","unstructured":"Menicali E, Guzzetti M, Morelli S, Moretti S, Puxeddu E (2020) Immune landscape of thyroid cancers: new insights. Front Endocrinol (Lausanne) 11:637826","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2410_CR10","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hed.27695","volume":"46","author":"B Febrero","year":"2024","unstructured":"Febrero B, Ruiz-Manzanera JJ, Ros-Madrid I, Hern\u00e1ndez AM, Orenes-Pi\u00f1ero E, Rodr\u00edguez JM (2024) Tumor microenvironment in thyroid cancer: Immune cells, patterns, and novel treatments. Head Neck 46(6):1486\u20131499","journal-title":"Head Neck"},{"key":"2410_CR11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fendo.2018.00314","volume":"9","author":"M Rotondi","year":"2018","unstructured":"Rotondi M, Coperchini F, Latrofa F, Chiovato L (2018) Role of chemokines in thyroid cancer microenvironment: Is CXCL8 the main player? Front Endocrinol (Lausanne) 9:314","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2410_CR12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1359-6101(01)00016-8","volume":"12","author":"K Xie","year":"2001","unstructured":"Xie K (2001) Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12(4):375\u2013391","journal-title":"Cytokine Growth Factor Rev"},{"issue":"8","key":"2410_CR13","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/carcin\/bgu060","volume":"35","author":"W Fang","year":"2014","unstructured":"Fang W, Ye L, Shen L, Cai J, Huang F, Wei Q et al (2014) Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. Carcinogenesis 35(8):1780\u20131787","journal-title":"Carcinogenesis"},{"issue":"22","key":"2410_CR14","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-13-3203","volume":"20","author":"MF Sanmamed","year":"2014","unstructured":"Sanmamed MF, Carranza-Rua O, Alfaro C, O\u00f1ate C, Mart\u00edn-Algarra S, Perez G et al (2014) Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res 20(22):5697\u20135707","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2410_CR15","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/bcp.12724","volume":"80","author":"S Jurcevic","year":"2015","unstructured":"Jurcevic S, Humfrey C, Uddin M, Warrington S, Larsson B, Keen C (2015) The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br J Clin Pharmacol 80(6):1324\u20131336","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2410_CR16","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.3324\/haematol.2016.152371","volume":"102","author":"M Uddin","year":"2017","unstructured":"Uddin M, Betts C, Robinson I, Malmgren A, Humfrey C (2017) The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates. Haematologica 102(2):e65\u2013e68","journal-title":"Haematologica"},{"key":"2410_CR17","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3389\/fimmu.2019.01419","volume":"10","author":"S Sody","year":"2019","unstructured":"Sody S, Uddin M, Gr\u00fcneboom A, G\u00f6rgens A, Giebel B, Gunzer M et al (2019) Distinct spatio-temporal dynamics of tumor-associated neutrophils in small tumor lesions. Front Immunol 10:1419","journal-title":"Front Immunol"},{"issue":"2","key":"2410_CR18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/0008-5472.CAN-12-0263","volume":"73","author":"P Saintigny","year":"2013","unstructured":"Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S et al (2013) CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73(2):571\u2013582","journal-title":"Cancer Res"},{"issue":"1","key":"2410_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2007.12.004","volume":"13","author":"L Yang","year":"2008","unstructured":"Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M et al (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13(1):23\u201335","journal-title":"Cancer Cell"},{"issue":"6","key":"2410_CR20","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","volume":"29","author":"CW Steele","year":"2016","unstructured":"Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L et al (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29(6):832\u2013845","journal-title":"Cancer Cell"},{"issue":"6","key":"2410_CR21","first-page":"5699","volume":"18","author":"F Guo","year":"2019","unstructured":"Guo F, Long L, Wang J, Wang Y, Liu Y, Wang L et al (2019) Insights on CXC chemokine receptor 2 in breast cancer: an emerging target for oncotherapy. Oncol Lett 18(6):5699\u20135708","journal-title":"Oncol Lett"},{"issue":"22","key":"2410_CR22","doi-asserted-by":"crossref","first-page":"35946","DOI":"10.18632\/oncotarget.16412","volume":"8","author":"F Liotti","year":"2017","unstructured":"Liotti F, De Pizzol M, Allegretti M, Prevete N, Melillo RM (2017) Multiple anti-tumor effects of Reparixin on thyroid cancer. Oncotarget 8(22):35946\u201335961","journal-title":"Oncotarget"},{"issue":"3","key":"2410_CR23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/cancers14030515","volume":"14","author":"S Safarulla","year":"2022","unstructured":"Safarulla S, Madan A, Xing F, Chandrasekaran A (2022) CXCR2 mediates distinct neutrophil behavior in brain metastatic breast tumor. Cancers 14(3):515","journal-title":"Cancers"},{"issue":"4","key":"2410_CR24","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1007\/s13277-015-4418-7","volume":"37","author":"F Coperchini","year":"2016","unstructured":"Coperchini F, Pignatti P, Carbone A, Bongianino R, Di Buduo CA, Leporati P et al (2016) TNF-\u03b1 increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer. Tumour Biol 37(4):5569\u20135575","journal-title":"Tumour Biol"},{"key":"2410_CR25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pupt.2017.05.012","volume":"45","author":"H Watz","year":"2017","unstructured":"Watz H, Uddin M, Pedersen F, Kirsten A, Goldmann T, Stellmacher F et al (2017) Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma. Pulm Pharmacol Ther 45:121\u2013123","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"2410_CR26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-018-0236-x","volume":"18","author":"M Cullberg","year":"2018","unstructured":"Cullberg M, Arfvidsson C, Larsson B, Malmgren A, Mitchell P, W\u00e4hlby Hamr\u00e9n U et al (2018) Pharmacokinetics of the oral selective CXCR2 antagonist azd5069: a summary of eight phase I studies in healthy volunteers. Drugs R D 18(2):149\u2013159","journal-title":"Drugs R D"},{"key":"2410_CR27","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot087171","author":"LC Crowley","year":"2016","unstructured":"Crowley LC, Christensen ME, Waterhouse NJ (2016) Measuring survival of adherent cells with the colony-forming assay. Cold Spring Harb Protoc. https:\/\/doi.org\/10.1101\/pdb.prot087171","journal-title":"Cold Spring Harb Protoc"},{"key":"2410_CR28","doi-asserted-by":"crossref","DOI":"10.1016\/j.envpol.2020.114778","volume":"264","author":"F Coperchini","year":"2020","unstructured":"Coperchini F, Croce L, Denegri M, Pignatti P, Agozzino M, Netti GS et al (2020) Adverse effects of in vitro GenX exposure on rat thyroid cell viability, DNA integrity and thyroid-related genes expression. Environ Pollut 264:114778","journal-title":"Environ Pollut"},{"issue":"23","key":"2410_CR29","doi-asserted-by":"crossref","first-page":"16738","DOI":"10.1074\/jbc.M112.431528","volume":"288","author":"V Abbonante","year":"2013","unstructured":"Abbonante V, Gruppi C, Rubel D, Gross O, Moratti R, Balduini A (2013) Discoidin domain receptor 1 protein is a novel modulator of megakaryocyte-collagen interactions. J Biol Chem 288(23):16738\u201316746","journal-title":"J Biol Chem"},{"issue":"1","key":"2410_CR30","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1210\/jc.2012-2555","volume":"98","author":"M Rotondi","year":"2013","unstructured":"Rotondi M, Coperchini F, Pignatti P, Sideri R, Groppelli G, Leporati P et al (2013) Interferon-\u03b3 and tumor necrosis factor-\u03b1 sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation? J Clin Endocrinol Metab 98(1):308\u2013313","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2410_CR31","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1038\/s41598-019-40818-w","volume":"9","author":"F Coperchini","year":"2019","unstructured":"Coperchini F, Croce L, Denegri M, Awwad O, Ngnitejeu ST, Muzza M et al (2019) The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors. Sci Rep 9(1):4390","journal-title":"Sci Rep"},{"issue":"60","key":"2410_CR32","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.18632\/oncotarget.27266","volume":"10","author":"F Coperchini","year":"2019","unstructured":"Coperchini F, Croce L, Denegri M, Awwad O, Ngnitejeu ST, Magri F et al (2019) The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes. Oncotarget 10(60):6432\u20136443","journal-title":"Oncotarget"},{"key":"2410_CR33","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s40618-018-0862-8","volume":"41","author":"O Awwad","year":"2018","unstructured":"Awwad O, Coperchini F, Pignatti P, Denegri M, Massara S, Croce L et al (2018) The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration. J Endocrinol Invest 41:1275\u20131282","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2410_CR34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/vaccines4030022","volume":"4","author":"JM David","year":"2016","unstructured":"David JM, Dominguez C, Hamilton DH, Palena C (2016) The IL-8\/IL-8R axis: a double agent in tumor immune resistance. Vaccines 4(3):22","journal-title":"Vaccines"},{"key":"2410_CR35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2017.08.004","volume":"60","author":"C Alfaro","year":"2017","unstructured":"Alfaro C, Sanmamed MF, Rodr\u00edguez-Ruiz ME, Teijeira \u00c1, O\u00f1ate C, Gonz\u00e1lez \u00c1 et al (2017) Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev 60:24\u201331","journal-title":"Cancer Treat Rev"},{"key":"2410_CR36","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107692","volume":"219","author":"K Fousek","year":"2021","unstructured":"Fousek K, Horn LA, Palena C (2021) Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacol Ther 219:107692","journal-title":"Pharmacol Ther"},{"issue":"8","key":"2410_CR37","doi-asserted-by":"crossref","first-page":"R465","DOI":"10.1530\/ERC-19-0163","volume":"26","author":"F Coperchini","year":"2019","unstructured":"Coperchini F, Croce L, Marin\u00f2 M, Chiovato L, Rotondi M (2019) Role of chemokine receptors in thyroid cancer and immunotherapy. Endocr Relat Cancer 26(8):R465\u2013R478","journal-title":"Endocr Relat Cancer"},{"issue":"24","key":"2410_CR38","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1016\/j.febslet.2009.10.036","volume":"583","author":"T Maier","year":"2009","unstructured":"Maier T, G\u00fcell M, Serrano L (2009) Correlation of mRNA and protein in complex biological samples. FEBS Lett 583(24):3966\u20133973","journal-title":"FEBS Lett"},{"issue":"10","key":"2410_CR39","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","volume":"4","author":"PM O\u2019Byrne","year":"2016","unstructured":"O\u2019Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M et al (2016) Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 4(10):797\u2013806","journal-title":"Lancet Respir Med"},{"key":"2410_CR40","doi-asserted-by":"crossref","first-page":"5273201","DOI":"10.1155\/2017\/5273201","volume":"2017","author":"CK M\u00e5rdh","year":"2017","unstructured":"M\u00e5rdh CK, Root J, Uddin M, Stenvall K, Malmgren A, Karabelas K et al (2017) Targets of neutrophil influx and weaponry: therapeutic opportunities for chronic obstructive airway disease. J Immunol Res 2017:5273201","journal-title":"J Immunol Res"},{"issue":"5","key":"2410_CR41","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4049\/jimmunol.1900543","volume":"204","author":"L Cristinziano","year":"2020","unstructured":"Cristinziano L, Modestino L, Loffredo S, Varricchi G, Braile M, Ferrara AL et al (2020) Anaplastic thyroid cancer cells induce the release of mitochondrial extracellular DNA traps by viable neutrophils. J Immunol 204(5):1362\u20131372","journal-title":"J Immunol"},{"issue":"6","key":"2410_CR42","first-page":"1405","volume":"63","author":"M Wislez","year":"2003","unstructured":"Wislez M, Rabbe N, Marchal J, Milleron B, Crestani B, Mayaud C et al (2003) Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res 63(6):1405\u20131412","journal-title":"Cancer Res"},{"key":"2410_CR43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cytogfr.2016.08.002","volume":"31","author":"Q Liu","year":"2016","unstructured":"Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T et al (2016) The CXCL8-CXCR1\/2 pathways in cancer. Cytokine Growth Factor Rev 31:61\u201371","journal-title":"Cytokine Growth Factor Rev"},{"key":"2410_CR44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1479-5876-12-7","volume":"12","author":"J Wang","year":"2014","unstructured":"Wang J, Jia Y, Wang N, Zhang X, Tan B, Zhang G et al (2014) The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J Transl Med 12:7","journal-title":"J Transl Med"},{"issue":"28","key":"2410_CR45","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1038\/s41388-019-0832-4","volume":"38","author":"Y Naito","year":"2019","unstructured":"Naito Y, Yamamoto Y, Sakamoto N, Shimomura I, Kogure A, Kumazaki M et al (2019) Cancer extracellular vesicles contribute to stromal heterogeneity by inducing chemokines in cancer-associated fibroblasts. Oncogene 38(28):5566\u20135579","journal-title":"Oncogene"},{"issue":"7","key":"2410_CR46","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/molecules25071618","volume":"25","author":"BL Rapoport","year":"2020","unstructured":"Rapoport BL, Steel HC, Theron AJ, Smit T, Anderson R (2020) Role of the neutrophil in the pathogenesis of advanced cancer and impaired responsiveness to therapy. Molecules 25(7):1618","journal-title":"Molecules"},{"issue":"4","key":"2410_CR47","doi-asserted-by":"crossref","first-page":"1700970","DOI":"10.1183\/13993003.00970-2017","volume":"51","author":"F Pedersen","year":"2018","unstructured":"Pedersen F, Waschki B, Marwitz S, Goldmann T, Kirsten A, Malmgren A et al (2018) Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils. Eur Respir J 51(4):1700970","journal-title":"Eur Respir J"},{"key":"2410_CR48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fimmu.2019.00047","volume":"10","author":"M Uddin","year":"2019","unstructured":"Uddin M, Watz H, Malmgren A, Pedersen F (2019) NETopathic inflammation in chronic obstructive pulmonary disease and severe asthma. Front Immunol 10:47","journal-title":"Front Immunol"},{"issue":"5","key":"2410_CR49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008662","volume":"12","author":"G Xiong","year":"2024","unstructured":"Xiong G, Chen Z, Liu Q, Peng F, Zhang C, Cheng M et al (2024) CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs. J Immunother Cancer 12(5):e008662","journal-title":"J Immunother Cancer"},{"issue":"6676","key":"2410_CR50","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/33340","volume":"392","author":"M Baggiolini","year":"1998","unstructured":"Baggiolini M (1998) Chemokines and leukocyte traffic. Nature 392(6676):565\u2013568","journal-title":"Nature"},{"issue":"2","key":"2410_CR51","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.canlet.2008.04.050","volume":"267","author":"J Vandercappellen","year":"2008","unstructured":"Vandercappellen J, Van Damme J, Struyf S (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett 267(2):226\u2013244","journal-title":"Cancer Lett"},{"issue":"3","key":"2410_CR52","doi-asserted-by":"crossref","first-page":"E427","DOI":"10.1210\/jc.2014-3045","volume":"100","author":"M Rotondi","year":"2015","unstructured":"Rotondi M, Coperchini F, Pignatti P, Magri F, Chiovato L (2015) Metformin reverts the secretion of CXCL8 induced by TNF-\u03b1 in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug. J Clin Endocrinol Metab 100(3):E427\u2013E432","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2410_CR53","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/s41467-022-29000-5","volume":"13","author":"P Zhang","year":"2022","unstructured":"Zhang P, Guan H, Yuan S, Cheng H, Zheng J, Zhang Z et al (2022) Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors. Nat Commun 13(1):1588","journal-title":"Nat Commun"},{"issue":"10","key":"2410_CR54","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","volume":"71","author":"J Leslie","year":"2022","unstructured":"Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F et al (2022) CXCR2 inhibition enables NASH-HCC immunotherapy. Gut 71(10):2093\u20132106","journal-title":"Gut"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02410-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02410-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02410-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T12:56:07Z","timestamp":1736772967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02410-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["2410"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02410-6","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors F.C, A.G, E.P, L.C, M.T, B.C, P.P, F.M and M.R declare they have no actual or potential competing financial interests. M.U is an employee of AstraZeneca and holds shares in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval was obtained from the ethics committee of ICS-Maugeri, Pavia, Italy. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"The study was approved by the Institutional Board of ICS-Maugeri, Pavia, Italy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Before surgery, written informed consent to the study was obtained from all patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}